According to a report, two courses of the newly approved agent blinatumomab, for relapsed or refractory B-cell precursor ALL, will cost a staggering $178,000.
Hematologic Cancer Targets
The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.
An oral inhibitor of isocitrate dehydrogenase 2 (IDH2), AG-221, has shown activity and potentially durable remissions in patients with acute myeloid leukemia.
A single cycle of blinatumomab resulted in complete minimal residual disease response in 78% of patients with acute lymphoblastic leukemia.
Early consolidation therapy with brentuximab vedotin after autologous stem cell transplant improved progression-free survival of patients with Hodgkin lymphoma.
The anti-PD-1 drug pembrolizumab demonstrated promising anti-tumor activity in patients with heavily pretreated classic Hodgkin lymphoma.
In this podcast from the 2014 American Society of Hematology Annual Meeting, we discuss some of the new developments in multiple myeloma.
The anti–PD-1 (programmed death 1) antibody nivolumab has shown activity in patients with hematologic cancers who have failed three or more prior therapies.
Adding carfilzomib to lenalidomide and dexamethasone resulted in a higher PFS and better overall quality of life for relapsed multiple myeloma patients.
T-lymphoblastic leukemia (T-ALL) should no longer be considered a poor-risk disease in the pediatric population, according to data presented at ASH.